Researchers found that when the drugs were used to treat dermatological conditions, the risk of acne was significantly higher than when they were used to treat other ailments.
Side effects of Xeljanz, Rinvoq, Olumiant and Other Janus Kinase (JAK) inhibitors linked to higher cancer risk than TNF inhibitors, like Humira and Enbrel
Researchers said neither the side effects of Xeljanz, or similar drugs appear to increase the risk of venous thromboembolism-related injuries.
Xeljanz, Jakafi and other JAK inhibitors were linked to an increased risk of melanoma, squamous cell carcinoma and Merkel cell carcinoma
The manufacturer also expects the FDA to reject approval for the drug for the treatment of atopic dermatitis due to FDA safety cocerns.
Cancer and heart risks linked to Rinvoq, Xeljanz and similar drugs have regulated them to secondary treatment options for rheumatoid arthritis.
Study claims heart risks with Olumiant are the same as those of rheumatoid arthritis patients not taking the drug, raising questions about a class-wide warning after concerns about the side effects of Xeljanz emerged
More research is needed into the link between Xeljanz and heart problems to determine how much of the risk is caused by side effects of the drugs, or the condition they are designed to treat, the researchers note
